17 October 2022 | Monday | News
Dr. Alexander Shneider, CEO of CureLab Oncology
Dr. Shneider is the CEO of CureLab Oncology, bringing more than 25 years of biotech and entrepreneurial experience. He is currently a senior research fellow of molecular biology at the University of Ariel, Israel; and an editorial board member for the journals Aging and International Reviews of Immunology.
His past achievements and activities include drug development, patents in all major jurisdictions, advisory role for successful exits, consultant for Fortune 100 companies, establishing and leading international R&D consortia, and a senior authorship role in papers and books. Alex holds a PhD. in life science and MSc. in molecular biotechnology. Connect with Dr. Shneider at firstname.lastname@example.org.
Cancer is the second-most deadly disease in the Asia-Pacific region. Cancer among women is becoming increasingly important in the region, where breast cancer is now one of the leading forms of cancer.
CureLab Oncology has demonstrated with statistical significance that its lead product, Elenagen, is clinically efficient in combatting the deadliest form of ovarian cancer, platinum-resistant ovarian cancer. Also, preliminary clinical results have demonstrated promising effects for the deadliest form of breast cancer, triple-negative breast cancer. Clinical testing in other forms of cancer relevant to APAC region will follow.
Also, Elenagen leverages the power of plasmids, a circular DNA that encodes a specific gene, p62. Plasmids represent a more cost-effective approach than other modern forms of cancer treatments, such as monoclonal antibodies or cell therapy. This means that a plasmid-based therapy can provide an attainable clinical solution to a broad spectrum of countries and patients, not only to the richest ones, without placing an enormous financial burden on the healthcare system in those countries.
We have defined a four-step strategy:
We are looking at all diseases of chronic inflammation, including age-associated diseases, metabolic syndrome and Type 2 diabetes, osteoporosis and arthritis, cardiovascular (including hypertension), CNS (including Alzheimer’s), psychiatric diseases (including depression), and dermatological conditions (including psoriasis).
CureLab Oncology’s sister company, CureLab Veterinary, is applying the same plasmid-based therapy for the treatment of canine and feline cancers, osteoarthritis, IBD, and aging. Again, we are seeing very encouraging results in our clinical studies: we saved 10 out of 11 dogs with breast cancer.
COVID is a killer for patients with chronic inflammation: elderly patients, patients with diabetes, hypertension, and so on. All these conditions are manifestations of chronic inflammation, which we mitigate. Thus, our product could become a crucial element of reducing COVID mortality and reducing the severity of COVID in high-risk groups.
We also know that post-COVID complications such as cardiovascular disorders are a direct result of COVID-induced chronic inflammation. We are hopeful that our product could become a crucial element of a treatment regimen to reduce post-COVID syndromes.